Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ted M Burns

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
Neurology|May 6, 2018
Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRIKelly G Gwathmey, Reza Sadjadi, William B Horton, et al.
Neurology|June 17, 2016
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravisMamatha Pasnoor, Jianghua He, Laura Herbelin, et al.
Muscle & Nerve|December 22, 2018
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravisKatherine M Clifford, Lisa D Hobson-Webb, Michael Benatar, et al.
Translational Neurodegeneration|October 29, 2025
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseasesGang Wu, Wenan Chen, Joanne Wuu, et al.
Muscle & Nerve|May 26, 2016
International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15rTed M Burns, Reza Sadjadi, Kimiaki Utsugisawa, et al.
Neurology|December 3, 2021
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyRichard J Nowak, Christopher S Coffey, Jonathan M Goldstein, et al.
EMBO Molecular Medicine|December 3, 2020
Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosisKaterina Placek, Michael Benatar, Joanne Wuu, et al.
Muscle & Nerve|December 15, 2015
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridineTed M Burns, Gordon A Smith, Jeffrey A Allen, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
Neurology|May 6, 2018
Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRIKelly G Gwathmey, Reza Sadjadi, William B Horton, et al.
Neurology|June 17, 2016
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravisMamatha Pasnoor, Jianghua He, Laura Herbelin, et al.
Muscle & Nerve|December 22, 2018
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravisKatherine M Clifford, Lisa D Hobson-Webb, Michael Benatar, et al.
Translational Neurodegeneration|October 29, 2025
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseasesGang Wu, Wenan Chen, Joanne Wuu, et al.
Muscle & Nerve|May 26, 2016
International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15rTed M Burns, Reza Sadjadi, Kimiaki Utsugisawa, et al.
Neurology|December 3, 2021
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyRichard J Nowak, Christopher S Coffey, Jonathan M Goldstein, et al.
EMBO Molecular Medicine|December 3, 2020
Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosisKaterina Placek, Michael Benatar, Joanne Wuu, et al.
Muscle & Nerve|December 15, 2015
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridineTed M Burns, Gordon A Smith, Jeffrey A Allen, et al.
Pageof 9